NCT06660498View on ClinicalTrials.gov

Pomalidomide as an Immune-enhancing Agent for the Control of HIV

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 13, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
HIV-1 Infection
Interventions
DRUG

Pomalidomide 2 mg

Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.

DRUG

Placebo

Participants will receive placebo concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.

DRUG

Aspirin 75 mg

Auxiliary Medicinal Product

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

Royal Melbourne Hospital, Melbourne

RECRUITING

Aarhus University Hospital, Aarhus

All Listed Sponsors
lead

University of Aarhus

OTHER